Comparison of an immunoradiometric and an immunoluminometric assay for the evaluation of the tumour associated antigens CA 19-9 and CA 125MADER, R. M; STEGER, G. G; BRAUN, J et al.European journal of clinical chemistry and clinical biochemistry. 1994, Vol 32, Num 2, pp 85-90, issn 0939-4974Article

Double modulation of 5-fluorouracil by high-dose leucovorin and interferon α2b in advanced colorectal cancer : a phase I and a phase II study of weekly administrationSTEGER, G. G; MADER, R. M; DJAVANMARD, M. P et al.Journal of cancer research and clinical oncology. 1994, Vol 120, Num 5, pp 314-318, issn 0171-5216Article

GM-CSF in the treatment of a patient with severe methotrexate intoxicationSTEGER, G. G; MADER, R. M; GNANT, M. F. X et al.Journal of internal medicine. 1993, Vol 233, Num 6, pp 499-502, issn 0954-6820Article

Brain metastases free survival differs between breast cancer subtypesBERGHOFF, A; BAGO-HORVATH, Z; DIECKMANN, K et al.British journal of cancer. 2012, Vol 106, Num 3, pp 440-446, issn 0007-0920, 7 p.Article

Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancerMADER, R. M; SCHROLNBERGER, C; RIZOVSKI, B et al.International journal of clinical pharmacology and therapeutics. 2002, Vol 40, Num 12, pp 571-572, issn 0946-1965, 2 p.Conference Paper

Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disordersLOCKER, G. J; KAPIOTIS, S; WAGNER, O. F et al.British journal of haematology. 1999, Vol 105, Num 4, pp 912-919, issn 0007-1048Article

Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF : immune phenomena or drug toxicity ?LOCKER, G. J; SIMONITSCH, I; MADER, R. M et al.Breast cancer research and treatment. 1995, Vol 34, Num 3, pp 213-219, issn 0167-6806Article

Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancerMADER, R. M; STEGER, G. G; RIZOVSKI, B et al.British journal of clinical pharmacology. 1994, Vol 37, Num 3, pp 243-248, issn 0306-5251Article

Determination of methotrexate in human urine at nanomolar levels by high-performance liquid chromatography with column switchingMADER, R. M; RIZOVSKI, B; STEGER, G. G et al.Journal of chromatography. Biomedical applications. 1993, Vol 613, Num 2, pp 311-316, issn 0378-4347Article

Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complexGIESSRIGL, B; SCHMIDT, W. M; KALIPCIYAN, M et al.British journal of cancer. 2013, Vol 109, Num 10, pp 2751-2762, issn 0007-0920, 12 p.Article

A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexateHOBL, E.-L; JILMA, B; ERLACHER, L et al.Clinical and experimental rheumatology (Testo stampato). 2012, Vol 30, Num 2, pp 156-163, issn 0392-856X, 8 p.Article

Gene expression profiling of colon cancer reveals a broad molecular repertoire in 5-fluorouracil resistanceSCHMIDT, W. M; KALIPCIYAN, M; DORNSTAUDER, E et al.International journal of clinical pharmacology and therapeutics. 2003, Vol 41, Num 12, pp 624-625, issn 0946-1965, 2 p.Article

Interstitial methotrexate kinetics in primary breast cancer lesionsMÜLLER, M; BRUNNER, M; SCHMID, R et al.Cancer research (Baltimore). 1998, Vol 58, Num 14, pp 2982-2985, issn 0008-5472Article

5-Fluorouracil kinetics in the interstitial tumor space : Clinical response in breast cancer patientsMÜLLER, M; MADER, R. M; STEINER, B et al.Cancer research (Baltimore). 1997, Vol 57, Num 13, pp 2598-2601, issn 0008-5472Article

Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancerMADER, R. M; ZILG, H; SCHLAPPACK, O et al.Cancer chemotherapy and pharmacology. 1995, Vol 37, Num 1-2, pp 91-96, issn 0344-5704Article

Folate absorption in Crohn's diseaseSTEGER, G. G; MADER, R. M; VOGELSANG, H et al.Digestion. 1994, Vol 55, Num 4, pp 234-238, issn 0012-2823Article

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastasesBARTSCH, R; BERGHOFF, A; MADER, R. M et al.British journal of cancer. 2012, Vol 106, Num 1, pp 25-31, issn 0007-0920, 7 p.Article

Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor systemMAHNIK, S. N; LENZ, K; WEISSENBACHER, N et al.Chemosphere (Oxford). 2007, Vol 66, Num 1, pp 30-37, issn 0045-6535, 8 p.Article

Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancerMADER, R. M; SCHROLNBERGER, C; RIZOVSKI, B et al.British journal of cancer. 2003, Vol 88, Num 5, pp 782-787, issn 0007-0920, 6 p.Article

Resistance to 5-fluorouracilMADER, R. M; MÜLLER, M; STEGER, G. G et al.General pharmacology. 1998, Vol 31, Num 5, pp 661-666, issn 0306-3623Article

The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinomaSTEGER, G. G; GNANT, M. F; DJAVANMARD, M. P et al.Journal of cancer research and clinical oncology. 1997, Vol 123, Num 6, pp 317-324, issn 0171-5216Article

Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidineFINDENIG, G; MADER, R. M; FRITZER-SZEKERES, M et al.Oncology research. 1996, Vol 8, Num 5, pp 189-196, issn 0965-0407Article

Instability of the anticancer agent etoposide under in vitro culture conditionsMADER, R. M; STEGER, G. G; MOSER, K et al.Cancer chemotherapy and pharmacology. 1991, Vol 27, Num 5, pp 354-360, issn 0344-5704, 7 p.Article